January 2025: The federal MDL is expanding to include Mounjaro and other GLP-1 drugs
Plus, earnings week insights, where Pfizer may be headed next, and why pricing and access, not just weight-loss percentages, may end up being the real disruptors
That single-molecule design is what separates it from stacking three drugs: the pharmacokinetics are unified, and the once-weekly half-life comes from a fatty-acid modification similar to the one used on semaglutide and tirzepatide
Tirzepatide (Mounjaro) targets both GLP-1 and GIP receptors
In late 2025, the White House announced a deal with two drug companies to lower the cost of their GLP-1 drugs
I was very satisfied with how quick the doctor got in touch with me and how quick my medicine showed up in the mail